A retrospective study of Ixazomib Based Therapy to Progression Post-Induction Predicts Outcomes for Relapsed/Refractory Myeloma: Real World Data from a Multi-Site Israeli Registry Study
Latest Information Update: 19 Jun 2020
At a glance
- Drugs Ixazomib (Primary) ; Corticosteroid; Cyclophosphamide; Daratumumab; Dexamethasone; Lenalidomide; Pomalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
Most Recent Events
- 01 Jun 2020 Results published in the Annals of Hematology
- 03 Feb 2019 New trial record
- 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology